271 related articles for article (PubMed ID: 37261366)
1. Human papillomavirus vaccination in low- and middle-income countries: progression, barriers, and future prospective.
Ebrahimi N; Yousefi Z; Khosravi G; Malayeri FE; Golabi M; Askarzadeh M; Shams MH; Ghezelbash B; Eskandari N
Front Immunol; 2023; 14():1150238. PubMed ID: 37261366
[TBL] [Abstract][Full Text] [Related]
2. Experiences and lessons learned from 29 HPV vaccination programs implemented in 19 low and middle-income countries, 2009-2014.
Ladner J; Besson MH; Audureau E; Rodrigues M; Saba J
BMC Health Serv Res; 2016 Oct; 16(1):575. PubMed ID: 27737666
[TBL] [Abstract][Full Text] [Related]
3. Key decision-making factors for human papillomavirus (HPV) vaccine program introduction in low-and-middle-income-countries: Global and national stakeholder perspectives.
Guillaume D; Waheed DE; Schlieff M; Muralidharan K; Vorsters A; Limaye R
Hum Vaccin Immunother; 2022 Dec; 18(7):2150454. PubMed ID: 36485172
[TBL] [Abstract][Full Text] [Related]
4. Performance of 21 HPV vaccination programs implemented in low and middle-income countries, 2009-2013.
Ladner J; Besson MH; Rodrigues M; Audureau E; Saba J
BMC Public Health; 2014 Jun; 14():670. PubMed ID: 24981818
[TBL] [Abstract][Full Text] [Related]
5. Potential benefit of extended dose schedules of human papillomavirus vaccination in the context of scarce resources and COVID-19 disruptions in low-income and middle-income countries: a mathematical modelling analysis.
Bénard É; Drolet M; Laprise JF; Jit M; Prem K; Boily MC; Brisson M
Lancet Glob Health; 2023 Jan; 11(1):e48-e58. PubMed ID: 36521952
[TBL] [Abstract][Full Text] [Related]
6. National implementation of HPV vaccination programs in low-resource countries: Lessons, challenges, and future prospects.
Tsu VD; LaMontagne DS; Atuhebwe P; Bloem PN; Ndiaye C
Prev Med; 2021 Mar; 144():106335. PubMed ID: 33678232
[TBL] [Abstract][Full Text] [Related]
7. Human papillomavirus (HPV) vaccination: from clinical studies to immunization programs.
Murillo R; Ordóñez-Reyes C
Int J Gynecol Cancer; 2019 Oct; 29(8):1317-1326. PubMed ID: 31455660
[TBL] [Abstract][Full Text] [Related]
8. Status of HPV vaccine introduction and barriers to country uptake.
Gallagher KE; LaMontagne DS; Watson-Jones D
Vaccine; 2018 Aug; 36(32 Pt A):4761-4767. PubMed ID: 29580641
[TBL] [Abstract][Full Text] [Related]
9. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries.
Brisson M; Kim JJ; Canfell K; Drolet M; Gingras G; Burger EA; Martin D; Simms KT; Bénard É; Boily MC; Sy S; Regan C; Keane A; Caruana M; Nguyen DTN; Smith MA; Laprise JF; Jit M; Alary M; Bray F; Fidarova E; Elsheikh F; Bloem PJN; Broutet N; Hutubessy R
Lancet; 2020 Feb; 395(10224):575-590. PubMed ID: 32007141
[TBL] [Abstract][Full Text] [Related]
10. Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis.
Drolet M; Laprise JF; Martin D; Jit M; Bénard É; Gingras G; Boily MC; Alary M; Baussano I; Hutubessy R; Brisson M
Lancet Infect Dis; 2021 Nov; 21(11):1598-1610. PubMed ID: 34245682
[TBL] [Abstract][Full Text] [Related]
11. Single-Dose Human Papillomavirus Vaccination in Low- and Middle-Income Countries-Time for Implementation?
Gallant D; Tummers P; Weyers S; Merckx M
J Pediatr Adolesc Gynecol; 2021 Oct; 34(5):586-590. PubMed ID: 34144176
[TBL] [Abstract][Full Text] [Related]
12. What works for human papillomavirus vaccine introduction in low and middle-income countries?
Howard N; Gallagher KE; Mounier-Jack S; Burchett HED; Kabakama S; LaMontagne DS; Watson-Jones D
Papillomavirus Res; 2017 Dec; 4():22-25. PubMed ID: 29179865
[TBL] [Abstract][Full Text] [Related]
13. Implementation of human papillomavirus immunization in the developing world.
Kane MA; Serrano B; de Sanjosé S; Wittet S
Vaccine; 2012 Nov; 30 Suppl 5():F192-200. PubMed ID: 23199963
[TBL] [Abstract][Full Text] [Related]
14. Current global status & impact of human papillomavirus vaccination: Implications for India.
Sankaranarayanan R; Bhatla N; Basu P
Indian J Med Res; 2016 Aug; 144(2):169-180. PubMed ID: 27934795
[TBL] [Abstract][Full Text] [Related]
15. Public health impact and cost-effectiveness of switching from bivalent to nonavalent vaccine for human papillomavirus in Norway: incorporating the full health impact of all HPV-related diseases.
Diakite I; Nguyen S; Sabale U; Pavelyev A; Saxena K; Tajik AA; Wang W; Palmer C
J Med Econ; 2023; 26(1):1085-1098. PubMed ID: 37608730
[TBL] [Abstract][Full Text] [Related]
16. Current Status of Human Papillomavirus Infection and Introduction of Vaccination to the National Immunization Program in Korea: an Overview.
Kim MA; Han GH; Kim JH; Seo K
J Korean Med Sci; 2018 Dec; 33(52):e331. PubMed ID: 30584412
[TBL] [Abstract][Full Text] [Related]
17. Cancer Prevention Begins in Middle School: The Personal Advantages of HPV Immunization in Males.
Gordon J; Bail J
NASN Sch Nurse; 2023 May; 38(3):114-120. PubMed ID: 36691362
[TBL] [Abstract][Full Text] [Related]
18. Factors Influencing the Cost-Effectiveness Outcomes of HPV Vaccination and Screening Interventions in Low-to-Middle-Income Countries (LMICs): A Systematic Review.
Okeah BO; Ridyard CH
Appl Health Econ Health Policy; 2020 Oct; 18(5):641-654. PubMed ID: 32468410
[TBL] [Abstract][Full Text] [Related]
19. A case study using the United Republic of Tanzania: costing nationwide HPV vaccine delivery using the WHO Cervical Cancer Prevention and Control Costing Tool.
Hutubessy R; Levin A; Wang S; Morgan W; Ally M; John T; Broutet N
BMC Med; 2012 Nov; 10():136. PubMed ID: 23146319
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study.
Jit M; Brisson M; Portnoy A; Hutubessy R
Lancet Glob Health; 2014 Jul; 2(7):e406-14. PubMed ID: 25103394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
